Skip to main content
. 2021 May 17;12(14):4229–4239. doi: 10.7150/jca.50472

Table 3.

Univariate and Multivariate analyses in patients (n=66) with Allo-HSCT

EFS OS
HR (95%CI) P-value HR (95%CI) P-value
Univariate analysis
RhoBTB3 (High vs Low) 1.200 (0.701-2.055) 0.506 1.036 (0.552-1.946) 0.912
age (≥60 vs <60) 0.845 (0.459-1.556) 0.588 1.195 (0.579-2.468) 0.629
Gender (Male vs Female) 0.954 (0.550-1.657) 0.869 0.805 (0.427-1.516) 0.502
WBC (≥100 vs <100×109) 1.537 (0.602-3.924) 0.369 2.212 (0.756-6.470) 0.147
RUNX1 mutation (Yes vs No) 0.762 (0.325-1.787) 0.532 1.256 (0.485-3.249) 0.639
TP53 mutation (Yes vs No) 1.650 (0.509-5.346) 0.404 4.559 (1.319-15.755) 0.016
ASXL1 mutation (Yes vs No) 0.679 (0.164-2.803) 0.593 0.518 (0.071-3.789) 0.517
NPM1 mutation (Yes vs No) 0.863 (0.475-1.567) 0.628 0.904 (0.450-1.816) 0.776
FLT3-ITD mutation (Yes vs No) 1.934 (1.041-3.591) 0.037 2.029 (0.969-4.247) 0.061
biCEBPA mutation (Yes vs No) 0.617 (0.150-2.546) 0.504 0.712 (0.169-2.989) 0.642
Multivariate analysis
TP53 mutation (Yes vs No) - - 5.732 (1.611-20.398) 0.007
FLT3-ITD mutation (Yes vs No) 1.934 (1.041-3.591) 0.037 2.288 (1.076-4.866) 0.031